Compared with the Model group, DSG treatment significantly reduced ET-1-positive area across all dose groups (all P < 0.05) and significantly increased eNOS-positive area in the DSG-M ( P = 0.0195) and DSG-H groups ( P < 0.001), while the DSG-L group showed an increasing trend in eNOS expression without statistical significance ( P = 0.7760).
Crucially, comparative analysis revealed that 38 of these metabolites—which were significantly dysregulated in the Model group—exhibited a pronounced trend of reversal following DSG-H intervention.
Effect of DSG on body weight, cardiac index, and serum lipid profiles As shown in Figure 3A , compared to the Control group, the Model and treatment groups exhibited a decreasing trend in body weight following the 6-week modeling period.
However, after drug administration, the DSG-H, DSG-M, and Positive groups showed a trend of weight recovery compared to the Model group.